Nanoshells for drug delivery

• US 8,048,448 B2
• Filed: 06/15/2006
• Issued: 11/01/2011
• Est. Priority Date: 06/15/2006
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Davalian, Dariush, Pacetti, Stephen D., Ludwig, Florian N., Hossainy, Syed F. A.
• Primary Examiner(s): Krass; Frederick
• Assistant Examiner(s): Shomer; Isaac
• Application Number:
  US11/454,813
• Publication Number:
  US 20070292495A1
• Time in Patent Office: 1,965 Days
• Field of Search: None
• US Class Current: 424/450
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/5115 Inorganic compounds

Abstract

Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.

Claims

1. A nano-construct comprising

(a) a metal or metal alloy nanoshell formed around a core material, and

(b) a bioactive agent,

wherein the core material comprises a material selected from the group consisting of a liposome, a polymersome, and a hybrid vesicle comprising both lipid and polymer-based constituents,

wherein the core material further comprises dielectric material, which comprises magnetic ceramic particles.

2. The nano-construct of claim 1, wherein the nanoshell is a gold nanoshell.

3. The nano-construct of claim 1, comprising a large unilamellar vesicle,

wherein the large unilamellar vesicle encapsulates the nanoshell and the bioactive agent.

4. The nano-construct of claim 1, wherein the core material is a small unilamellar vesicle encapsulating the bioactive agent.

5. The nano-construct of claim 1, wherein the nanoshell is a gold nanoshell having a thickness in the range between about 5 and about 25 nm.

6. The nano-construct of claim 1, wherein the core material is a liposome having a size in the range between about 150 nm to about 200 nm.

7. The nano-construct of claim 1, wherein the metal or metal alloy nanoshell surrounding the core is porous to the bioactive agent once it is released from the core material.

8. The nano-construct of claim 2, wherein the gold nanoshell surrounds the core of a dielectric material, and

wherein a plurality of these gold shells are conjugated to the surface of the core material, which contains the bioactive agent.

9. The nano-construct of claim 1, wherein the core material comprises a peptide, a protein, or a combination of these.

10. The nano-construct of claim 1, further comprising a targeting molecule on the surface of the nano-construct.

11. The nano-construct of claim 10, wherein the targeting molecule is a surface-conjugated ligand against one or more receptors on an inflamed endothelium.

12. The nano-construct of claim 1 in a formulation suitable for systemic delivery or local delivery into a human being.

13. The nano-construct of claim 12, wherein the systemic delivery is injection.

14. The nano-construct of claim 12, wherein the local delivery is delivery by a device comprising a catheter.

15. The nano-construct of claim 1, wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin, γ

-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, or combinations of these.

16. A method of forming a nano-construct according to claim 1, comprising:

providing a core material selected from a liposome, a polymerosome, a hybrid vesicle,

forming a nanoshell around the core material.

17. The method of claim 16, wherein the core material encapsulates a bioactive agent.

18. The method of claim 16, wherein the formed nanoshell has porosity.

19. The method of claim 16, wherein the core material is a liposome.

20. The method of claim 16, wherein the nanoshell is a gold nanoshell having a thickness in the range between about 5 and about 25 nm.

21. The method of claim 16, wherein the liposome has a size in the range between about 150 nm to about 200 nm.

22. The method of claim 16, wherein the core material comprises a peptide, a protein, or a combination of these.

23. The method of claim 16, wherein the nano-construct comprises a targeting molecule on the surface of the nano-construct.

24. The method of claim 23, wherein the targeting molecule is a suface-conjugated ligand against receptors on an inflamed endothelium.

25. The method of claim 16, wherein the nano-construct is in a formulation suitable for systemic delivery or local delivery into a human being.

26. The method of claim 25, wherein the systemic delivery is injection.

27. The method of claim 25, wherein the local delivery is delivery by a device comprising a catheter.

28. The method of claim 16, wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin, γ

-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, or combinations of these.